Siemens' RAPIDPoint 500e Blood Gas Analyzer Receives US FDA Clearance to Aid in COVID-19 Care
By HospiMedica International staff writers Posted on 01 Apr 2020 |
Image: The RAPIDPoint 500e Blood Gas Analyzer (Photo courtesy of Siemens Healthineers)
Siemens Healthineers’ (Erlangen, Germany) latest critical care testing solution, the RAPIDPoint 500e Blood Gas Analyzer, has received clearance from the US Food and Drug Administration, and is now available in the US, Europe and countries requiring the CE mark. The RAPIDPoint 500e Blood Gas Analyzer belongs to Siemens’ blood gas portfolio which is supporting COVID-19 response efforts, where blood gas testing plays a critical role in managing infected patients.
The RAPIDPoint 500e Blood Gas Analyzer generates blood gas, electrolyte, metabolite, CO-oximetry, and neonatal bilirubin results, which are used to diagnose and monitor critically ill patients in the intensive care unit, operating room, or emergency room. Blood gas testing is often required for ventilator-assisted patients and those undergoing evaluation for respiratory distress, providing insights into a patient’s oxygenation level. Additionally, the RAPIDPoint 500e Blood Gas Analyzer uses Integri-sense Technology, a comprehensive series of automated functional checks that are designed to deliver accurate test results at the point-of-care.
“Point-of-care teams monitoring respiratory conditions in critical care settings need a blood gas testing solution that delivers fast, accurate results and increases workflow efficiencies. A safe operating environment amid growing concerns about cybersecurity threats in healthcare is also important,” said Christoph Pedain, Head of Point of Care Diagnostics, Siemens Healthineers. “The RAPIDPoint 500e Blood Gas Analyzer has become a trusted instrument in Europe’s endeavor to combat COVID-19 and to help address an unprecedented demand for blood gas testing in affected respiratory patients.”
Related Links:
Siemens Healthineers
The RAPIDPoint 500e Blood Gas Analyzer generates blood gas, electrolyte, metabolite, CO-oximetry, and neonatal bilirubin results, which are used to diagnose and monitor critically ill patients in the intensive care unit, operating room, or emergency room. Blood gas testing is often required for ventilator-assisted patients and those undergoing evaluation for respiratory distress, providing insights into a patient’s oxygenation level. Additionally, the RAPIDPoint 500e Blood Gas Analyzer uses Integri-sense Technology, a comprehensive series of automated functional checks that are designed to deliver accurate test results at the point-of-care.
“Point-of-care teams monitoring respiratory conditions in critical care settings need a blood gas testing solution that delivers fast, accurate results and increases workflow efficiencies. A safe operating environment amid growing concerns about cybersecurity threats in healthcare is also important,” said Christoph Pedain, Head of Point of Care Diagnostics, Siemens Healthineers. “The RAPIDPoint 500e Blood Gas Analyzer has become a trusted instrument in Europe’s endeavor to combat COVID-19 and to help address an unprecedented demand for blood gas testing in affected respiratory patients.”
Related Links:
Siemens Healthineers
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans